GLP-1 medicines including Ozempic and Wegovy face fresh safety scrutiny over a possible link to NAION, a rare condition causing sudden vision loss. European regulators classify NAION as a very rare semaglutide side effect, while Novo Nordisk's trial data found no increased incidence. US federal courts now list 216 pending lawsuits over the alleged risk.
GLP-1 Drugs Face Scrutiny Over Rare Eye Condition NAION
Source: Mint